1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline characteristics of patients
No Tirofiban (n = 279) Tirofiban (n = 35) P Value
Age (median) (IQR) (yr) 69.0 (60.0–76.0) 66.0 (55.5–73.0) .163
Sex (male) 144 (51.6%) 24 (68.6%) .086
Hypertension 174 (62.4%) 18 (51.4%) .286
DM 60 (21.5%) 9 (25.7%) .726
Hyperlipidemia 75 (26.9%) 12 (34.3%) .470
Prior antiplatelet 89 (31.9%) 7 (20.0%) .213
Prior anticoagulant 29 (10.4%) 1 (2.9%) .261
NIHSS on admission (median) (IQR) 17.0 (13.0–20.0) 16.0 (12.0–20.0) .448
Onset-to-puncture time (min, median) (IQR) 204.0 (153.0–257.5) 184.0 (150.0–281.5) .622
Onset-to-final angiography time (min, median) (IQR) 273.0 (214.5–349.0) 303.0 (241.0–348.5) .230
Etiology of LVO <.001
 Embolic occlusion 231 (82.8%) 16 (45.7%) 
 ICAS occlusion 28 (10.0%) 18 (51.4%) 
Intractable (failed thrombectomy) 20 (7.2%) 1 (2.9%) 
Target artery occlusion .725
 Terminal ICA 113 (40.5%) 11 (31.4%) 
 MCA M1 139 (49.8%) 20 (57.1%) 
 MCA M2 27 (9.7%) 4 (11.4%) 
Intraprocedural reocclusion 10 (3.6%) 11 (31.4%) <.001
Intracranial stent placement 9 (3.2%) 6 (17.1%) .001
Intracranial ballooning 8 (2.9%) 0 (0.0%) .656
ASPECTS (median) (IQR) 7.0 (4.0–9.0) 8.0 (4.5–9.5) .899
Note:—IQR indicates interquartile range; DM, diabetes mellitus; ICAS, intracranial atherosclerotic stenosis.